Literature DB >> 26375182

Dasatinib therapy can result in significant pulmonary toxicity.

Maciek Tatarczuch1, Kate Burbury1, Louise Creati2, Elchanan H Januszewicz1, John F Seymour1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26375182     DOI： 10.1002/ajh.24194

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  3 in total

Review 1.  Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Authors:  Lauren Caldemeyer; Michael Dugan; John Edwards; Luke Akard
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

2.  The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.

Authors:  Lucy C Fox; Katherine D Cummins; Ben Costello; David Yeung; Rebecca Cleary; Cecily Forsyth; Maciek Tatarczuch; Kate Burbury; Olga Motorna; Jake Shortt; Shaun Fleming; Andrew McQuillan; Anthony Schwarer; Rosemary Harrup; Amy Holmes; Sumita Ratnasingam; Kah-Lok Chan; Wei-Hsun Hsu; Asma Ashraf; Faye Putt; Andrew Grigg
Journal:  Blood Adv       Date:  2017-05-15

Review 3.  Pneumocystis jirovecii-associated immune reconstitution inflammatory syndrome-like phenomenon in a child with leukaemia: a case report and literature review.

Authors:  Jia-Ying Lei; Han Chen; Dun-Hua Zhou; Lu-Hong Xu; Jian-Pei Fang; You-Gang Mai
Journal:  BMC Pediatr       Date:  2022-07-12       Impact factor: 2.567
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.